路透社：Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine https://www.reuters.com/legal/moderna-sues-pfizerbiontech-patent-infringement-over-covid-vaccine-2022-08-26/ 在周五的声明中，Moderna 表示辉瑞/BioNTech 挪用了两种类型的知识产权。 其中一个涉及一种 mRNA 结构，Moderna 称其科学家于 2010 年开始开发，并于 2015 年率先在人体试验中进行验证。“辉瑞和 BioNTech 将四种不同的候选疫苗进行了临床测试，其中包括避开 Moderna 创新道路的选项。然而，最终，辉瑞和 BioNTech 最终决定用一种与Moderna其疫苗具有相同 mRNA 化学修饰的疫苗 ”摩德纳说。 第二项涉嫌侵权涉及编码一种全长刺突蛋白。 In Friday''s statement, Moderna said Pfizer/BioNTech appropriated two types of intellectual property. One involved an mRNA structure that Moderna says its scientists began developing in 2010 and were the first to validate in human trials in 2015. "Pfizer and BioNTech took four different vaccine candidates into clinical testing, which included options that would have steered clear of Moderna''s innovative path. Pfizer and BioNTech, however, ultimately decided to proceed with a vaccine that has the same exact mRNA chemical modification to its vaccine," Moderna said. The second alleged infringement involves the coding of a full-length spike protein that Moderna says its scientists developed while creating a vaccine for the coronavirus that causes Middle East Respiratory Syndrome (MERS). Although the MERS vaccine never went to market, its development helped Moderna rapidly roll out its COVID-19 vaccine.
这是什么情况？ 感觉这次Covid,风头都被Pfizer抢了。
在周五的声明中，Moderna 表示辉瑞/BioNTech 挪用了两种类型的知识产权。
其中一个涉及一种 mRNA 结构，Moderna 称其科学家于 2010 年开始开发，并于 2015 年率先在人体试验中进行验证。“辉瑞和 BioNTech 将四种不同的候选疫苗进行了临床测试，其中包括避开 Moderna 创新道路的选项。然而，最终，辉瑞和 BioNTech 最终决定用一种与Moderna其疫苗具有相同 mRNA 化学修饰的疫苗 ”摩德纳说。
第二项涉嫌侵权涉及编码一种全长刺突蛋白。
In Friday''s statement, Moderna said Pfizer/BioNTech appropriated two types of intellectual property.
One involved an mRNA structure that Moderna says its scientists began developing in 2010 and were the first to validate in human trials in 2015. "Pfizer and BioNTech took four different vaccine candidates into clinical testing, which included options that would have steered clear of Moderna''s innovative path. Pfizer and BioNTech, however, ultimately decided to proceed with a vaccine that has the same exact mRNA chemical modification to its vaccine," Moderna said.
The second alleged infringement involves the coding of a full-length spike protein that Moderna says its scientists developed while creating a vaccine for the coronavirus that causes Middle East Respiratory Syndrome (MERS). Although the MERS vaccine never went to market, its development helped Moderna rapidly roll out its COVID-19 vaccine.